Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (DE:07X)
BERLIN:07X
Annovis Bio (07X) Stock Price & Analysis
1 Followers
07X Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€5.11 - €18.10
Previous Close€14.72
Volume140.00
Average Volume (3M)590.00
Market Cap
€185.29M
Enterprise Value€179.36M
Total Cash (Recent Filing)$6.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta>-0.01
Next Earnings
May 09, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,011,299
10 Day Avg. Volume0
30 Day Avg. Volume590
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)29.78
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.83
Forecast
1Y Price Target
€23.59Price Target Upside60.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Annovis Bio News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressBuntanetap pivotal trial in Alzheimer's disease completed with enrollment exceeding its original target, and a very low dropout rate, indicating robust participation and data.
Drug Safety ProfileDuring the safety analysis, no drug-related serious adverse events were reported for buntanetap and adverse events were less than 5%, suggesting a favorable safety profile.
Investment AnalysisAnalyst reiterates a Buy rating with a 12-month target based on discounted cash flow valuation methodology, signaling a positive investment outlook.
Bears Say
Clinical Trial OutcomesA statistically significant improvement in MDS-UPDRS II has not been recorded as a primary outcome in a Ph.3 PD trial.
Earnings PerformanceAnnovis Bio recorded a full-year net loss of $6.23 per share, substantially wider than the forecast.
Financial HealthThe company will require approximately $350 million in cash to reach cash flow positivity in 2029, while currently having about $5 million in cash on hand.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
07X FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was €5.11 and its highest was €18.10 in the past 12 months.
What is Annovis Bio’s market cap?
Currently, no data Available
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is May 09, 2024 which is in 10 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Apr 02, 2024. The company reported -€2.092 earnings per share for the quarter, missing the consensus estimate of -€0.827 by -€1.265.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Annovis Bio have?
Currently, no data Available
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -€2.092 in its last earnings report, missing expectations of -€0.827. Following the earnings report the stock price went up 0.734%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in DE:07X
---
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€23.59 (60.27% Upside)
€23.59 (60.27% Upside)
Blogger Sentiment
Bullish
DE:07X Sentiment 87%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.19%
12-Months-Change
Fundamentals
Return on Equity
-546.40%
Trailing 12-Months
Asset Growth
-71.66%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio Inc is a United States based clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
---
07X Stock 12 Months Forecast
Average Price Target
€23.59
▲(60.27% Upside)
Technical Analysis
Best Analysts Covering 07X
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+36.09%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +36.09% per trade.
---